Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 51 Solid TresibaⓇ performance strengthens total insulin market share in Japan Japanese basal value market shares TresibaⓇ LevemirⓇ --- glargine U100- - glargine U300 Japanese total insulin value market shares Eli Lilly Sanofi NN Total Basal - NPH - biosimilar glargine 80% Novo Nordisk 80% 70% 60% 50% 40% 30% 20% 10% 0% Aug 2013 Source: IMS Monthly August, 2016 value figures changing diabetes® 51% 60% 40% 40% 34% 11% 8% 20% 4% 3% 0% Aug 2016 Aug 2013 Source: IMS Monthly August, 2016 value figures 58% 23% 19% Aug 2016 novo nordisk

View entire presentation